Botulinum toxin in the treatment of chronic migraine: a systematic revision

Detalhes bibliográficos
Autor(a) principal: Mello, Andriele do Prado
Data de Publicação: 2023
Outros Autores: Jacociunas, Laura Vicedo
Tipo de documento: Artigo
Idioma: por
Título da fonte: Clinical and Biomedical Research
Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/125718
Resumo: Chronic migraine is caused by chemical changes in the brain, unilateral, pulsating pain of varying intensity. The administration of botulinum toxin, a neurotoxin produced by Clostridium botulinum, is an alternative treatment. There are different preparations of botulinum toxin, capable of inhibiting the release of acetylcholine, promoting muscle relaxation. The aim of the study was to analyze the therapeutic efficacy of botulinum toxin in the treatment of chronic migraine. A systematic review was carried out using the Main Items to Report Systematic Reviews and Meta-Analyses method as a supporting tool, using as descriptors: chronic migraine, botulinum toxin and treatment. Twenty-one articles were analyzed, of which 6 were meta-analyses and 15 were clinical trials, 9 clinical trials were compared to placebo and 6 to other therapies. The trials used a range of doses from 75 to 260 IU, and included patients with episodic and chronic migraine, in which the toxin was most effective. The toxin also had a good safety profile, with few adverse effects reported, which were generally mild or moderate. The study concluded that controlled clinical trials indicate that botulinum toxin type A was effective in treating chronic migraine. In comparison with the other drugs, it showed similar efficacy and a superior tolerability profile.
id UFRGS-20_805f6739bb30975da6a61c45b56d98e5
oai_identifier_str oai:seer.ufrgs.br:article/125718
network_acronym_str UFRGS-20
network_name_str Clinical and Biomedical Research
repository_id_str
spelling Botulinum toxin in the treatment of chronic migraine: a systematic revisionToxina botulínica no tratamento da enxaqueca crônica: uma revisão sistemáticaEnxaquecaToxina BotulínicaClostridium botulinumChronic migraine is caused by chemical changes in the brain, unilateral, pulsating pain of varying intensity. The administration of botulinum toxin, a neurotoxin produced by Clostridium botulinum, is an alternative treatment. There are different preparations of botulinum toxin, capable of inhibiting the release of acetylcholine, promoting muscle relaxation. The aim of the study was to analyze the therapeutic efficacy of botulinum toxin in the treatment of chronic migraine. A systematic review was carried out using the Main Items to Report Systematic Reviews and Meta-Analyses method as a supporting tool, using as descriptors: chronic migraine, botulinum toxin and treatment. Twenty-one articles were analyzed, of which 6 were meta-analyses and 15 were clinical trials, 9 clinical trials were compared to placebo and 6 to other therapies. The trials used a range of doses from 75 to 260 IU, and included patients with episodic and chronic migraine, in which the toxin was most effective. The toxin also had a good safety profile, with few adverse effects reported, which were generally mild or moderate. The study concluded that controlled clinical trials indicate that botulinum toxin type A was effective in treating chronic migraine. In comparison with the other drugs, it showed similar efficacy and a superior tolerability profile.A enxaqueca crônica é causada por alterações químicas do cérebro, dores unilaterais, pulsáteis de intensidade variável. A administração da toxina botulínica, neurotoxina produzida pelo Clostridium botulinum, é uma alternativa de tratamento. Existem diferentes preparações da toxina botulínica, capaz de inibir a liberação de acetilcolina, provocando uma inibição da contração muscular. O objetivo do estudo foi analisar a eficácia terapêutica da toxina botulínica no tratamento da enxaqueca crônica. Foi realizada uma revisão sistemática utilizando como ferramenta embasadora o método de Principais Itens para Relatar Revisões Sistemáticas e Meta-Análises, utilizando como descritores: enxaqueca crônica, toxina botulínica e tratamento. Foram analisados 21 artigos, sendo 6 metas-analises e 15 ensaios clínicos, 9 ensaios clínicos foram comparados a placebo e 6 a outras terapias. Os ensaios utilizaram uma variedade de doses de 75 até 260 UI, e incluíram pacientes com enxaqueca episódica e crônica, na qual a toxina mostrou maior eficácia. A toxina apresentou também um perfil bom de segurança, sendo relatados poucos efeitos adversos, que em geral foram leves ou moderados. O estudo concluiu que ensaios clínicos controlados indicam que a toxina botulínica tipo A foi eficaz no tratamento da enxaqueca crônica. Na comparação com os demais medicamentos demostrou eficácia semelhante perfil de tolerabilidade superior. HCPA/FAMED/UFRGS2023-09-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed Systematic Reviewapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/125718Clinical & Biomedical Research; Vol. 43 No. 2 (2023): Clinical and Biomedical ResearchClinical and Biomedical Research; v. 43 n. 2 (2023): Clinical and Biomedical Research2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSporhttps://seer.ufrgs.br/index.php/hcpa/article/view/125718/89708Copyright (c) 2023 Andriele do Prado Mello, Laura Vicedo Jacociunashttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMello, Andriele do PradoJacociunas, Laura Vicedo2024-01-19T14:11:21Zoai:seer.ufrgs.br:article/125718Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2024-01-19T14:11:21Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.none.fl_str_mv Botulinum toxin in the treatment of chronic migraine: a systematic revision
Toxina botulínica no tratamento da enxaqueca crônica: uma revisão sistemática
title Botulinum toxin in the treatment of chronic migraine: a systematic revision
spellingShingle Botulinum toxin in the treatment of chronic migraine: a systematic revision
Mello, Andriele do Prado
Enxaqueca
Toxina Botulínica
Clostridium botulinum
title_short Botulinum toxin in the treatment of chronic migraine: a systematic revision
title_full Botulinum toxin in the treatment of chronic migraine: a systematic revision
title_fullStr Botulinum toxin in the treatment of chronic migraine: a systematic revision
title_full_unstemmed Botulinum toxin in the treatment of chronic migraine: a systematic revision
title_sort Botulinum toxin in the treatment of chronic migraine: a systematic revision
author Mello, Andriele do Prado
author_facet Mello, Andriele do Prado
Jacociunas, Laura Vicedo
author_role author
author2 Jacociunas, Laura Vicedo
author2_role author
dc.contributor.author.fl_str_mv Mello, Andriele do Prado
Jacociunas, Laura Vicedo
dc.subject.por.fl_str_mv Enxaqueca
Toxina Botulínica
Clostridium botulinum
topic Enxaqueca
Toxina Botulínica
Clostridium botulinum
description Chronic migraine is caused by chemical changes in the brain, unilateral, pulsating pain of varying intensity. The administration of botulinum toxin, a neurotoxin produced by Clostridium botulinum, is an alternative treatment. There are different preparations of botulinum toxin, capable of inhibiting the release of acetylcholine, promoting muscle relaxation. The aim of the study was to analyze the therapeutic efficacy of botulinum toxin in the treatment of chronic migraine. A systematic review was carried out using the Main Items to Report Systematic Reviews and Meta-Analyses method as a supporting tool, using as descriptors: chronic migraine, botulinum toxin and treatment. Twenty-one articles were analyzed, of which 6 were meta-analyses and 15 were clinical trials, 9 clinical trials were compared to placebo and 6 to other therapies. The trials used a range of doses from 75 to 260 IU, and included patients with episodic and chronic migraine, in which the toxin was most effective. The toxin also had a good safety profile, with few adverse effects reported, which were generally mild or moderate. The study concluded that controlled clinical trials indicate that botulinum toxin type A was effective in treating chronic migraine. In comparison with the other drugs, it showed similar efficacy and a superior tolerability profile.
publishDate 2023
dc.date.none.fl_str_mv 2023-09-05
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Systematic Review
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/125718
url https://seer.ufrgs.br/index.php/hcpa/article/view/125718
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/125718/89708
dc.rights.driver.fl_str_mv Copyright (c) 2023 Andriele do Prado Mello, Laura Vicedo Jacociunas
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Andriele do Prado Mello, Laura Vicedo Jacociunas
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv HCPA/FAMED/UFRGS
publisher.none.fl_str_mv HCPA/FAMED/UFRGS
dc.source.none.fl_str_mv Clinical & Biomedical Research; Vol. 43 No. 2 (2023): Clinical and Biomedical Research
Clinical and Biomedical Research; v. 43 n. 2 (2023): Clinical and Biomedical Research
2357-9730
reponame:Clinical and Biomedical Research
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Clinical and Biomedical Research
collection Clinical and Biomedical Research
repository.name.fl_str_mv Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv ||cbr@hcpa.edu.br
_version_ 1799767057424711680

Registros relacionados